News
MDXG
3.575
+0.42%
0.015
Weekly Report: what happened at MDXG last week (0504-0508)?
Weekly Report · 1d ago
MiMedx: The Hard Math Behind My Downgrade To Hold
Seeking Alpha · 3d ago
MIMEDX Announces Launch of G4Derm® Plus
Barchart · 4d ago
Weekly Report: what happened at MDXG last week (0427-0501)?
Weekly Report · 05/04 10:32
TELA Bio names Joseph Capper board chair in four-director refreshment plan
PUBT · 04/30 21:30
TELA BIO INC - CHAIRMAN DOUG EVANS, KURT AZARBARZIN, VINCE BURGESS, FEDERICA O’BRIEN TO DEPART BOARD
Reuters · 04/30 20:43
MiMedx Group Price Target Cut to $6.00/Share From $7.00 by Citizens
Dow Jones · 04/30 15:24
MiMedx Group Is Maintained at Market Outperform by Citizens
Dow Jones · 04/30 15:24
Citizens Maintains Market Outperform on MiMedx Group, Lowers Price Target to $6
Benzinga · 04/30 15:15
MiMedx price target lowered to $6 from $7 at Craig-Hallum
TipRanks · 04/30 15:00
MiMedx price target lowered to $5 from $10 at Lake Street
TipRanks · 04/30 14:56
MiMedx price target lowered to $6 from $7 at Citizens
TipRanks · 04/30 09:56
Mimedx expects $260M-$290M 2026 net sales amid $40M cost cuts and wound care reimbursement disruption
Seeking Alpha · 04/30 03:43
MiMedx cuts FY26 revenue view to $260M-$290M from $340M-$360M
TipRanks · 04/29 20:40
MiMedx Group Non-GAAP EPS of -$0.05 misses by $0.01, revenue of $59M misses by $6.8M
Seeking Alpha · 04/29 20:26
MiMedx Q1 sales fall 33%, miss estimates, cuts 2026 outlook
Reuters · 04/29 20:15
MiMedx Group Lowers FY2026 Sales Guidance from $340.000M-$360.000M to $260.000M-$290.000M vs $307.000M Est
Benzinga · 04/29 20:12
MiMedx Group Q1 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $58.991M Miss $65.020M Estimate
Benzinga · 04/29 20:06
MiMedx Q1 FY26 net loss widens to $11 million; net sales fall 33% to $59 million
PUBT · 04/29 20:02
BRIEF-MiMedx Q1 Sales USD 58.991 Million Vs. IBES Estimate USD 65 Million
Reuters · 04/29 20:01
More
Webull provides a variety of real-time MDXG stock news. You can receive the latest news about Mimedx Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MDXG
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.